Clinical Trial

Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 20, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The prognosis of most patients with unresectable locally advanced or metastatic colorectal cancer (CRC) remains poor despite the advancements in chemotherapy and target therapy. CAPability-01 trial investigated the potential efficacy of combining the programmed cell death protein-1 (PD-1) monoclonal antibody sintilimab with the histone deacetylase inhibitor (HDACi) chidamide with or without the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab in patients with unresectable chemotherapy-refractory locally advanced or metastatic microsatellite stable/proficient mismatch repair (MSS/pMMR) colorectal cancer. Based on the previous findings of CAPability-01, we will further evaluate the efficacy and safety of sintilimab and chidamide in combination with fruquintinib in the same setting.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-11.
Trial Details
NCT Number NCT06685276
Lead Sponsor Dai, Guanghai
Conditions Colorectal Cancer Metastatic
Enrollment 46 participants
Start Date 2024-08-16
Primary Completion 2025-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-11-20